Unilateral biportal endoscopic lumbar interbody fusion versus minimally invasive transforaminal lumbar interbody fusion in the treatment of lumbar degenerative diseases: a retrospective multicenter cohort study

单侧双通道内镜下腰椎椎间融合术与微创经椎间孔腰椎椎间融合术治疗腰椎退行性疾病的比较:一项回顾性多中心队列研究

阅读:1

Abstract

BACKGROUND: Minimally invasive transforaminal lumbar interbody fusion (Mis-TLIF) is one of the most commonly used methods for lumbar fusion. However, in recent years, the unilateral biportal endoscopic lumbar interbody fusion (UBE-LIF) has also gradually attracted the attention of spine surgeons. This study aims to compare the perioperative and long-term clinical outcomes of the two procedures for lumbar degenerative diseases (LDD). METHODS: We collected clinical data of patients who had undergone minimally invasive transforaminal lumbar interbody fusion (Mis-TLIF) or unilateral biportal endoscopic lumbar interbody fusion (UBE-LIF) for lumbar degenerative diseases (LDD) from January 2019 to December 2022. The primary outcome measure was the Oswestry Disability Index (ODI) at 12 months postoperatively. Secondary outcome measures included 12-month visual analog scale (VAS) scores for low back pain (LBP) and leg pain (LP), and postoperative complication rate. RESULTS: There were no significant differences in the preoperative VAS scores for LBP, LP, or ODI between the two groups. The VAS score for LBP was significantly lower in the UBE-LIF group than in the Mis-TLIF group 1 week postoperatively (1.4 ± 1.1 vs. 2.1 ± 1.0, P = 0.001). However, there was no significant difference in the VAS scores for LBP, LP, and ODI at 1, 6, and 12 months postoperatively. The length of stay was significantly lower in the UBE-LIF than in the Mis-TLIF group (5.2 ± 1.1 vs. 6.3 ± 1.2 days, P < 0.001). The operative time (188.9 ± 19.8 vs. 159.5 ± 11.6 minutes, P < 0.001) of the UBE-LIF group was significantly higher than that of the Mis-TLIF group, while the estimated blood loss (131.0 ± 21.9 vs. 191.7 ± 23.3 ml, P < 0.001) and postoperative drainage volume (123.0 ± 55.4 vs. 191.2 ± 47.5 ml, P < 0.001) were significantly lower in the UBE-LIF than in the Mis-TLIF group. The complication rate was slightly higher in the UBE-LIF than in the Mis-TLIF group; however, the difference was not significant (11.5% vs. 5.0%, P = 0.299). CONCLUSION: UBE-LIF can achieve better perioperative clinical outcomes than Mis-TLIF. However, in the long-term, these two procedures can achieve equivalent clinical efficacy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。